Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
Debra Van Egeren(Stanford University), Sahand Hormoz(Broad Institute), Ann Mullally(VA Palo Alto Health Care System), Fernando D. Camargo(Harvard Stem Cell Institute), Maximilian Nguyen(Harvard University), Marlise R. Luskin(Dana-Farber Cancer Institute), Maria Kalyva(European Bioinformatics Institute), Baransel Kamaz(Brigham and Women's Hospital), Martha Wadleigh(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Javier Escabi(Harvard University), Christopher R. Reilly(Dana-Farber Cancer Institute), Gabriela Hobbs(Massachusetts General Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Isidro Cortés‐Ciriano(European Bioinformatics Institute), Franziska Michor(Dana-Farber Cancer Institute), Sachin Patel(Boston Children's Hospital), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Shichen Liu(Dana-Farber Cancer Institute), Eric S. Winer(Providence College)
Cited by 209
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k